StreetInsider.com News Articles

Form 6-K GH Research PLC For: Jun 04

Thu, 04 Jun 2026 08:36:00 -0400

si-local-file:///var/storage/secattach/20260604/26603046.html

Form 6-K GH Research PLC For: Jun 04

Thu, 04 Jun 2026 08:36:00 -0400

si-local-file:///var/storage/secattach/20260604/26603046.html

GH Research publishes Phase 2a postpartum depression trial results

Thu, 04 Jun 2026 07:01:08 -0400

GH Research PLC (NASDAQ: GHRS) announced the publication of results from its Phase 2a trial of inhaled mebufotenin (GH001) for postpartum depression in The Journal of Clinical Psychiatry.

The single-arm, open-label trial enrolled 10 adult women with postpartum depression. The study met its primary endpoint with a mean Montgomery–Åsberg Depression Rating Scale reduction of 35.4 points from baseline to Day 8. All 10 patients achieved remission within two hours of dosing, which was sustained through Day 8.

The trial showed a 34.1-point increase on the Barkin Index of Maternal Functioning at Day 8, representing a 56% improvement. The treatment was well-tolerated with

GH Research publishes Phase 2a postpartum depression trial results

Thu, 04 Jun 2026 07:01:08 -0400

GH Research PLC (NASDAQ: GHRS) announced the publication of results from its Phase 2a trial of inhaled mebufotenin (GH001) for postpartum depression in The Journal of Clinical Psychiatry.

The trial showed a 34.1-point increase on the Barkin Index of Maternal Functioning at Day 8, representing a 56% improvement. The treatment was well-tolerated with

GH Research publishes Phase 2a postpartum depression trial results

Thu, 04 Jun 2026 07:01:08 -0400

GH Research PLC (NASDAQ: GHRS) announced the publication of results from its Phase 2a trial of inhaled mebufotenin (GH001) for postpartum depression in The Journal of Clinical Psychiatry.

The trial showed a 34.1-point increase on the Barkin Index of Maternal Functioning at Day 8, representing a 56% improvement. The treatment was well-tolerated with

GH Research publishes Phase 2a postpartum depression trial results

Thu, 04 Jun 2026 07:01:08 -0400

GH Research PLC (NASDAQ: GHRS) announced the publication of results from its Phase 2a trial of inhaled mebufotenin (GH001) for postpartum depression in The Journal of Clinical Psychiatry.

The trial showed a 34.1-point increase on the Barkin Index of Maternal Functioning at Day 8, representing a 56% improvement. The treatment was well-tolerated with

GH Research publishes Phase 2a postpartum depression trial results

Thu, 04 Jun 2026 07:01:08 -0400

GH Research PLC (NASDAQ: GHRS) announced the publication of results from its Phase 2a trial of inhaled mebufotenin (GH001) for postpartum depression in The Journal of Clinical Psychiatry.

The trial showed a 34.1-point increase on the Barkin Index of Maternal Functioning at Day 8, representing a 56% improvement. The treatment was well-tolerated with

GH Research publishes Phase 2a postpartum depression trial results

Thu, 04 Jun 2026 07:01:08 -0400

GH Research PLC (NASDAQ: GHRS) announced the publication of results from its Phase 2a trial of inhaled mebufotenin (GH001) for postpartum depression in The Journal of Clinical Psychiatry.

The trial showed a 34.1-point increase on the Barkin Index of Maternal Functioning at Day 8, representing a 56% improvement. The treatment was well-tolerated with

GH Research Announces Publication of Phase 2a Postpartum Depression Results